

Resource Summary Report

Generated by [kravitz2](#) on Aug 10, 2026

Ki-67

RRID:AB_10611571

Type: Antibody

Proper Citation

BD Biosciences Cat# 561277, RRID:AB_10611571

Antibody Information

URL: http://antibodyregistry.org/AB_10611571

Proper Citation: BD Biosciences Cat# 561277, RRID:AB_10611571

Target Antigen: Ki-67

Host Organism: mouse

Clonality: monoclonal

Comments: Intracellular staining (flow Cytotoxicityometry)

Antibody Name: Ki-67

Description: This monoclonal targets Ki-67

Target Organism: human

Antibody ID: AB_10611571

Vendor: BD Biosciences

Catalog Number: 561277

Record Creation Time: 20250819T231603+0000

Record Last Update: 20250820T044845+0000

Ratings and Alerts

- This antibody has been included in the HuBMAP's Organ Mapping Antibody Panels, please see specific validation data: <https://avr.hubmapconsortium.org> See: Human_Liver_Manual_IBEX.xlsx - The Human BioMolecular Atlas Program

No alerts have been found for Ki-67.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Freeburg NF, et al. (2026) The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell.

Moro A, et al. (2025) Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming. iScience, 28(6), 112553.

Karaliota S, et al. (2025) Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques. iScience, 28(4), 112232.

Humblin E, et al. (2025) The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells. Immunity, 58(8), 1966.

Broderick C, et al. (2025) A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer discovery, 15(8), 1717.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Hahn PA, et al. (2025) Exogenous estrogen enhances T cell activation in male primates. Cell reports, 44(9), 116170.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells. Immunity, 58(10), 2472.

Li S, et al. (2025) Protocol for multiplex immunofluorescence imaging of mouse intestinal tumors. STAR protocols, 6(2), 103776.

You S, et al. (2024) Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer cell, 42(8), 1415.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Englebert K, et al. (2024) The CD27/CD70 pathway negatively regulates visceral adipose tissue-resident Th2 cells and controls metabolic homeostasis. *Cell reports*, 43(3), 113824.

Müller TR, et al. (2024) Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. *Cell host & microbe*, 32(2), 156.

Pulliam T, et al. (2024) Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. *Cell reports. Medicine*, 5(2), 101412.

Wang G, et al. (2024) Adipose-tissue Treg cells restrain differentiation of stromal adipocyte precursors to promote insulin sensitivity and metabolic homeostasis. *Immunity*, 57(6), 1345.

Radtke AJ, et al. (2024) Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. *Cancer cell*, 42(3), 444.

Shouse AN, et al. (2024) Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets. *iScience*, 27(12), 111248.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. *Cancer cell*, 42(9), 1582.

Anderson TM, et al. (2024) FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1758.

Foskolou IP, et al. (2023) The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. *Cell reports*, 42(9), 113013.